Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?

Varsha Chiruvella, Asad Ullah, Islam Elhelf, Nikhil Patel, Nagla Abdel Karim

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Pericardial effusion is a common finding in advanced-stage lung cancer. The presence of malignant cells or drainage of exudate effusion in the pericardial space may cause symptoms of dyspnea, pleuritic chest pain, and syncope. In addition to the difficulty physicians face in the detection and diagnosis of malignant pericardial effusion, treatment may be challenging considering the cancer prognosis and cardiovascular stability of the patient. Despite the availability of several treatment modalities for malignant pericardial effusion, including chemotherapy and surgery, patients with lung cancer historically present with poor prognoses. In addition to lung adenocarcinoma with malignant pericardial effusion, this case was complicated by COVID-19 and malignancy-associated obstructive pneumonia. We present a case of a 64-year-old woman with advanced non-small cell lung carcinoma (NSCLC) with malignant pericardial effusion who, despite testing positive for COVID-19 and having obstructive pneumonia, had favorable outcomes following systemic therapy with combined chemo-immunotherapy.

Original languageEnglish (US)
Article number871132
JournalFrontiers in Oncology
StatePublished - May 6 2022


  • adenocarcinoma
  • combined chemoimmunotherapy
  • immunotherapy
  • malignant pericardial effusion
  • pneumonia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?'. Together they form a unique fingerprint.

Cite this